Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1

Expert Review of Vaccines

Volumn 9, Issue 9, 2010, Pages 1055-1069

  Paris, Robert M ^a   Kim, Jerome H ^b   Robb, Merlin L ^b,c   Michael, Nelson L ^b  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

Author keywords

DNA; HIV 1; vaccine; vector; virus

Indexed keywords

ADENOVIRUS VECTOR; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; POXVIRUS VECTOR; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS GLYCOPROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; ENZYME LINKED IMMUNOSPOT ASSAY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MAJOR CLINICAL STUDY; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POXVIRUS; PRIORITY JOURNAL; REVIEW; RHESUS MONKEY; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; THAILAND; VACCINE PRODUCTION; VIREMIA; VIRUS INHIBITION; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; PRIMATES; VACCINATION; VACCINIA VIRUS;

EID: 77956462839     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.106     Document Type: Review

References (158)

1. UNAIDS and World Health Organization. AIDS Epidemic Update 2009. UNAIDS and the WHO, Geneva, Switzerland (2009).
2. Pitisuttithum P, Gilbert P, Gurwith M et al. Randomized, double-blind, placebo-controlled effcacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J. Infect. Dis. 194(12), 1661-1671 (2006).
3. Buchbinder SP, Mehrotra DV, Duerr A et al Effcacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372(9653), 1881-1893 (2008).
4. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled Phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J. Infect. Dis. 191(5), 654-665 (2005).
5. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361(23), 2209-2220 (2009).
6. Robb ML. Failure of the Merck HIV vaccine: an uncertain step forward. Lancet 372(9653), 1857-1858 (2008).
7. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin. Infect. Dis. 47(3), 401-409 (2008).
8. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 455 (7213), 613-619 (2008).
9. Douek DC, Kwong PD, Nabel GJ. The rational design of an AIDS vaccine. Cell 124(4), 677-681 (2006).
10. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N. Engl. J. Med. 358(15), 1590-1602 (2008).
11. Burton DR, Desrosiers RC, Doms RW et al. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5(3), 233-236 (2004).
12. Excler JL, Plotkin S. The prime-boost concept applied to HIV preventive vaccines. AIDS 11 Suppl. A, S127-S137 (1997).
13. Ranasinghe C, Ramshaw IA. Genetic heterologous prime-boost vaccination strategies for improved systemic and mucosal immunity. Expert. Rev. Vaccines 8(9), 1171-1181 (2009).
14. Priddy FH, Brown D, Kublin J et al. Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin. Infect. Dis. 46(11), 1769-1781 (2008).
15. Harro CD, Robertson MN, Lally MA et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res. Hum. Retroviruses 25(1), 103-114 (2009).
16. Gudmundsdotter L, Nilsson C, Brave A et al. Recombinant Modifed Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specifc immune responses in humans despite pre-existing vaccinia immunity. Vaccine 27(33), 4468-4474 (2009).
17. McMichael AJ. HIV vaccines. Annu. Rev. Immunol. 24, 227-255 (2006).
18. + T cells. Blood 107(12), 4781-4789 (2006).
19. Kannanganat S, Kapogiannis BG, Ibegbu C et al. Human immunodefciency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J. Virol. 81(21), 12071-12076 (2007).
20. + T cells is refected by their avidity, polyfunctionality, and clonal turnover. J. Exp. Med. 204(10), 2473-2485 (2007).
21. + T-cell subsets in human immunodefciency virus controllers: an ANRS EP36 study. J. Virol. 81(24), 13904-13915 (2007).
22. Pereyra F, Addo MM, Kaufmann DE et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197(4), 563-571 (2008).
23. Limou S, Le Clerc S, Coulonges C et al. Genomewide association study of an AIDS-nonprogression cohort emphasizes the role played by HLA genes (ANRS Genomewide Association Study 02). J. Infect. Dis. 199(3), 419-426 (2009).
24. Fellay J, Shianna K V, Ge D et al. A whole-genome association study of major determinants for host control of HIV-1. Science 317(5840), 944-947 (2007).
25. Carrington M, Nelson GW, Martin MP et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283(5408), 1748-1752 (1999).
26. Gao X, Nelson GW, Karacki P et al. Effect of a single amino acid change in MHC class I molecules on the rate of progression to AIDS. N. Engl. J. Med. 344(22), 1668-1675 (2001).
27. Kaslow RA, Carrington M, Apple R et al. Infuence of combinations of human major histocompatibility complex genes on the course of HIV-1 infection. Nat. Med. 2(4), 405-411 (1996).
28. Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA. Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level. Science 296(5572), 1439-1443 (2002).
29. Brumme ZL, Brumme CJ, Heckerman D et al. Evidence of Differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1. PLoS Pathog. 3(7), e94 (2007).
30. Bhattacharya T, Daniels M, Heckerman D et al. Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science 315(5818), 1583-1586 (2007).
31. Kiepiela P, Leslie AJ, Honeyborne I et al. Dominant infuence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 432(7018), 769-775 (2004).
32. + elite suppressors despite CTL escape mutations. J. Exp. Med. 203(5), 1357-1369 (2006).
33. Pelak K, Goldstein DB, Walley NM et al. Host determinants of HIV-1 control in African Americans. J. Infect. Dis. 201(8), 1141-1149 (2010).
34. Migueles SA, Sabbaghian MS, Shupert ML. HLA B5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl Acad. Sci. USA 97, 2709-2714 (2000).
35. Goulder PJ, Brander C, Tang Y et al. Evolution and transmission of stable CTL escape mutations in HIV infection. Nature 412(6844), 334-338 (2001).
36. Goulder PJ, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nature Rev. Immunol. 4, 630-640 (2004).
37. Lu S, Santoro JC, Fuller DH, Haynes JR, Robinson HL. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 209(1), 147-154 (1995).
38. Lu S, Wyatt R, Richmond JF et al. Immunogenicity of DNA vaccines expressing human immunodefciency virus type 1 envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res. Hum. Retroviruses 14(2), 151-155 (1998).
39. MacGregor RR, Boyer JD, Ugen KE et al. First human trial of a DNA-based vaccine for treatment of human immunodefciency virus type 1 infection: safety and host response. J. Infect. Dis. 178(1), 92-100 (1998).
40. Catanzaro AT, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J. Infect. Dis. 194(12), 1638-1649 (2006).
41. Graham BS, Koup RA, Roederer M et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J. Infect. Dis. 194(12), 1650-1660 (2006).
42. Abdulhaqq SA, Weiner DB. DNA vaccines: developing new strategies to enhance immune responses. Immunol. Res. 42(1-3), 219-232 (2008).
43. Rosati M, Valentin A, Jalah R et al. Increased immune responses in rhesus macaques by DNA vaccination combined with electroporation. Vaccine 26(40), 5223-5229 (2008).
44. Patel V, Valentin A, Kulkarni V et al. Long-lasting humoral and cellular immune responses and mucosal dissemination after intramuscular DNA immunization. Vaccine 28(30), 4827-4836 (2010).
45. + T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat. Med. 16(3), 324-328 (2010).
46. Kwissa M, Kasturi SP, Pulendran B. The science of adjuvants. Expert. Rev. Vaccines 6(5), 673-684 (2007).
47. Kraynyak KA, Kutzler MA, Cisper NJ et al. Plasmid-encoded interleukin-15 receptor a enhances specifc immune responses induced by a DNA vaccine in vivo. Hum. Gene Ther. 20(10), 1143-1156 (2009).
48. Ourmanov I, Brown CR, Moss B et al. Comparative effcacy of recombinant modifed vaccinia virus Ankara expressing simian immunodefciency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74(6), 2740-2751 (2000).
49. Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodefciency-virus immunity. Nature 415(6869), 331-335 (2002).
50. + central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312(5779), 1530-1533 (2006).
51. Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292(5514), 69-74 (2001).
52. Wilson NA, Keele BF, Reed JS et al. Vaccine-induced cellular responses control simian immunodefciency virus replication after heterologous challenge. J. Virol. 83(13), 6508-6521 (2009).
53. + lymphocytes. Science 283(5403), 857-860 (1999).
54. Reynolds MR, Weiler AM, Weisgrau KL et al. Macaques vaccinated with live-attenuated SIV control replication of heterologous virus. J. Exp. Med. 205(11), 2537-2550 (2008).
55. Hansen SG, Vieville C, Whizin N et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodefciency virus challenge. Nat. Med. 15(3), 293-299 (2009).
56. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modifed vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79 (Pt 5), 1159-1167 (1998).
57. Moss B. Vaccinia virus: a tool for research and vaccine development. Science 252(5013), 1662-1667 (1991).
58. Moss B, Carroll MW, Wyatt LS et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397, 7-13 (1996).
59. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modifed vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3(3), 263-271 (2003).
60. Hanke T, Samuel RV, Blanchard TJ et al. Effective induction of simian immunodefciency virus-specifc cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modifed vaccinia virus Ankara boost vaccination regimen. J. Virol. 73(9), 7524-7532 (1999).
61. Allen TM, Vogel TU, Fuller DH et al. Induction of AIDS virus-specifc CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modifed vaccinia virus Ankara boost regimen. J. Immunol. 164(9), 4968-4978 (2000).
62. Amara RR, Villinger F, Staprans SI et al. Different patterns of immune responses but similar control of a simian-human immunodefciency virus 89.6P mucosal challenge by modifed vaccinia virus Ankara (MVA) and DNA/MVA vaccines. J. Virol. 76(15), 7625-7631 (2002).
63. + T-cell loss and higher titers of neutralizing antibody. J. Virol. 83(11), 5388-5400 (2009).
64. Gherardi MM, Perez-Jimenez E, Najera JL, Esteban M. Induction of HIV immunity in the genital tract after intranasal delivery of a MVA vector: enhanced immunogenicity after DNA prime-modifed vaccinia virus Ankara boost immunization schedule. J. Immunol. 172(10), 6209-6220 (2004).
65. Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6(2), 148-158 (2006).
66. Manrique M, Kozlowski PA, Wang SW et al. Nasal DNA-MVA SIV vaccination provides more signifcant protection from progression to AIDS than a similar intramuscular vaccination. Mucosal Immunol. 2(6), 536-550 (2009).
67. Gilbert PB, Chiu YL, Allen M et al. Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials. Vaccine 21(21-22), 2933-2947 (2003).
68. Jaoko W, Nakwagala FN, Anzala O et al. Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modifed vaccinia virus Ankara (MVA) in humans in East Africa. Vaccine 26(22), 2788-2795 (2008).
69. Dorrell L, Williams P, Suttill A et al. Safety and tolerability of recombinant modifed vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy. Vaccine 25(17), 3277-3283 (2007).
70. Peters BS, Jaoko W, Vardas E et al. Studies of a prophylactic HIV-1 vaccine candidate based on modifed vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity. Vaccine 25(11), 2120-2127 (2007).
71. Cebere I, Dorrell L, McShane H et al Phase I clinical trial safety of DNA-and modifed virus Ankara-vectored human immunodefciency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24(4), 417-425 (2006).
72. Mwau M, Cebere I, Sutton J et al. A human immunodefciency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specifc T-cell responses by DNA and recombinant modifed vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85(Pt 4), 911-919 (2004).
73. Hanke T, Goonetilleke N, McMichael AJ, Dorrell L. Clinical experience with plasmid DNA-and modifed vaccinia virus Ankara-vectored human immunodefciency virus type 1 clade A vaccine focusing on T-cell induction. J. Gen. Virol. 88(Pt 1), 1-12 (2007).
74. Guimaraes-Walker A, Mackie N, McCormack S et al. Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specifc T-cell responses in healthy volunteers. Vaccine 26(51), 6671-6677 (2008).
75. + T-cell epitopes. J. Virol. 80(10), 4717-4728 (2006).
76. Sandstrom E, Nilsson C, Hejdeman B et al Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modifed vaccinia virus ankara. J. Infect. Dis. 198(10), 1482-1490 (2008).
77. Currier J, de Souza M, Ratto-Kim S et al Characterization of cell-mediated immune responses generated by a recombinant modifed vaccinia Ankara (rMVA)-HIV-1 in a Phase I vaccine trial. AIDS Vaccine 2009. Paris, France (2009) (Abstract OA04-03).
78. Robinson H, Goepfert P, Hay C et al.; HVTN 065 Protocol Team. GeoVax clade B DNA/MVA HIV/AIDS vaccine is well tolerated and immunogenic when administered to healthy seronegative adults (HVTN 065 part A). Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 3-6 February 2008.
79. Vasan S, Schlesinger SJ, Huang Y et al Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccine. PLoS ONE 5(1), e8617 (2010).
80. Vasan S, Schlesinger SJ, Chen Z et al Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modifed vaccinia Ankara-HIV-1 B'/C candidate vaccine. PLoS ONE 5(1), e8816 (2010).
81. Ramanathan VD, Kumar M, Mahalingam J et al. A Phase 1 study to evaluate the safety and immunogenicity of a recombinant HIV type 1 subtype C-modifed vaccinia Ankara virus vaccine candidate in Indian volunteers. AIDS Res. Hum. Retroviruses 25 (11), 1107-1116 (2009).
82. Wild J, Bieler K, Kostler J et al. Preclinical evaluation of the immunogenicity of C-type HIV-1-based DNA and NYVAC vaccines in the Balb/C mouse model. Viral Immunol. 22(5), 309-319 (2009).
83. Harari A, Bart PA, Stohr W et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J. Exp. Med. 205(1), 63-77 (2008).
84. Bart PA, Goodall R, Barber T et al. EV01: a Phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine 26(25), 3153-3161 (2008).
85. Corbett M, Bogers WM, Heeney JL et al. Aerosol immunization with NYVAC and MVA vectored vaccines is safe, simple, and immunogenic. Proc. Natl Acad. Sci. USA 105(6), 2046-2051 (2008).
86. Esteban M. Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS. Hum. Vaccin. 5(12), 867-871 (2009).
87. Mooij P, Balla-Jhagjhoorsingh SS, Beenhakker N et al. Comparison of human and rhesus macaque T-cell responses elicited by boosting with NYVAC encoding human immunodefciency virus type 1 clade C immunogens. J. Virol. 83(11), 5881-5889 (2009).
88. Gomez CE, Najera JL, Jimenez V et al. Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C. Vaccine 25(11), 1969-1992 (2007).
89. Casimiro DR, Wang F, Schleif WA et al. Attenuation of simian immunodefciency virus SIVmac239 infection by prophylactic immunization with DNA and recombinant adenoviral vaccine vectors expressing Gag. J. Virol. 79(24), 15547-15555 (2005).
90. Fauci AS, Johnston MI, Dieffenbach CW et al. HIV vaccine research: the way forward. Science 321(5888), 530-532 (2008).
91. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat. Med. 14(6), 617-621 (2008).
92. Baden LR, Dolin R, O'Brien KL et al. OA05-06LB. First-in human Phase I safety and immunogenicity of an adenovirus serotype 26 HIV-1 vaccine vector. Retrovirology 6(Suppl. 3), O36 (2009).
93. Liu J, O'Brien KL, Lynch DM et al. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature 457, 87-91 (2008).
94. Asmuth DM, Brown EL, DiNubile MJ et al. Comparative cell-mediated immunogenicity of DNA/DNA, DNA/adenovirus type 5 (Ad5), or Ad5/Ad5 HIV-1 clade B gag vaccine prime-boost regimens. J. Infect. Dis. 201(1), 132-141 (2010).
95. Casimiro DR, Chen L, Fu TM et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodefciency virus type 1 gag gene. J. Virol. 77(11), 6305-6313 (2003).
96. Wilson NA, Reed J, Napoe GS et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodefciency virus SIVmac239. J. Virol. 80(12), 5875-5885 (2006).
97. McElrath MJ, De Rosa SC, Moodie Z et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372(9653), 1894-1905 (2008).
98. Buchbinder S, Robertson MN, Duerr A. Abstract SS01-02. Clinical outcomes from the Step study. Presented at: AIDS Vaccine 2009. Paris, France, 19-26 October 2009.
99. D'Souza MP, Frahm N. Adenovirus 5 serotype vector-specifc immunity and HIV-1 infection: a tale of T cells and antibodies. AIDS 24(6), 803-809 (2010).
100. Cox KS, Clair JH, Prokop MT et al. DNA gag/adenovirus type 5 (Ad5) gag and Ad5 gag/Ad5 gag vaccines induce distinct T-cell response profles. J. Virol. 82(16), 8161-8171 (2008).
101. Kibuuka H, Kimutai R, Maboko L et al. A Phase 1/2 study of a multiclade HIV-1 DNA plasmid prime and recombinant adenovirus serotype 5 boost vaccine in HIV-uninfected East Africans (RV 172). J. Infect. Dis. 201(4), 600-607 (2010).
102. Hu SL, Abrams K, Barber GN et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 255(5043), 456-459 (1992).
103. Cooney EL, McElrath MJ, Corey L et al. Enhanced immunity to human immunodefciency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein. Proc. Natl Acad. Sci. USA 90(5), 1882-1886 (1993).
104. Cooney EL, Collier AC, Greenberg PD et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337(8741), 567-572 (1991).
105. Graham BS, Matthews TJ, Belshe RB et al. Augmentation of human immunodefciency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 167(3), 533-537 (1993).
106. Graham BS, Belshe RB, Clements ML et al. Vaccination of vaccinia-naive adults with human immunodefciency virus type 1 gp160 recombinant vaccinia virus in a blinded, controlled, randomized clinical trial. The AIDS Vaccine Clinical Trials Network. J. Infect. Dis. 166(2), 244-252 (1992).
107. Sealy R, Slobod KS, Flynn P et al. Preclinical and clinical development of a multi-envelope, DNA-virus-protein (D-V-P) HIV-1 vaccine. Int. Rev. Immunol. 28(1), 49-68 (2009).
108. Franchini G, Gurunathan S, Baglyos L, Plotkin S, Tartaglia J. Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev. Vaccines 3(4 Suppl.), S75-S88 (2004).
109. Mascola JR, Stiegler G, VanCott TC et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6(2), 207-210 (2000).
110. Hessell AJ, Poignard P, Hunter M et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15(8), 951-954 (2009).
111. Hessell AJ, Rakasz EG, Poignard P et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5(5), e1000433 (2009).
112. Thongcharoen P, Suriyanon V, Paris RM et al. A Phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J. Acquir. Immune Defc. Syndr. 46(1), 48-55 (2007).
113. Russell ND, Graham BS, Keefer MC et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a Phase 3 correlates trial. J. Acquir. Immune Defc. Syndr. 44(2), 203-212 (2007)
114. AIDS Vaccine Evaluation Group 022 Protocol Team. Cellular and humoral immune responses to a canarypox vaccine containing human immunodefciency virus type 1 Env, Gag, and Pro in combination with rgp120. J. Infect. Dis. 183(4), 563-570 (2001).
115. Belshe RB, Stevens C, Gorse GJ et al. Safety and immunogenicity of a canarypox-vectored human immunodefciency virus type 1 vaccine with or without gp120: a Phase 2 study in higher-and lower-risk volunteers. J. Infect. Dis. 183(9), 1343-1352 (2001).
116. Salmon-Ceron D, Excler JL, Finkielsztejn L et al. Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. AIDS Res. Hum. Retroviruses 15(7), 633-645 (1999).
117. Belshe RB, Gorse GJ, Mulligan MJ et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12(18), 2407-2415 (1998).
118. + T-cell loss and reduces both systemic and mucosal simian-human immunodefciency virus SHIVKU2 RNA levels. J. Virol. 80(8), 3732-3742 (2006).
119. Pal R, Venzon D, Letvin NL et al. ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodefciency virus SIVmac-induced immunodefciency. J. Virol. 76(1), 292-302 (2002).
120. Santra S, Schmitz JE, Kuroda MJ et al. Recombinant canarypox vaccine-elicited CTL specifc for dominant and subdominant simian immunodefciency virus epitopes in rhesus monkeys. J. Immunol. 168(4), 1847-1853 (2002).
121. Van Rompay KK, Abel K, Lawson JR et al. Attenuated poxvirus-based simian immunodefciency virus (SIV) vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J. Acquir. Immune Defc. Syndr. 38(2), 124-134 (2005).
122. De Bruyn G, Rossini AJ, Chiu YL et al. Safety profle of recombinant canarypox HIV vaccines. Vaccine 22(5-6), 704-713 (2004).
123. Taylor J, Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 6(6), 466-468 (1988).
124. Baxby D, Paoletti E. Potential use of non-replicating vectors as recombinant vaccines. Vaccine 10(1), 8-9 (1992).
125. Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24, 739-769 (2006).
126. Pialoux G, Excler JL, Riviere Y et al. A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA. AIDS Res. Hum. Retroviruses 11(3), 373-381 (1995).
127. Clements-Mann ML, Weinhold K, Matthews TJ et al. Immune responses to human immunodefciency virus (HIV) type induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J. Infect. Dis. 177(5), 1230-1246 (1998).
128. Gupta K, Hudgens M, Corey L et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J. Acquir. Immune Defc. Syndr. 29(3), 254-261 (2002).
129. Lee D, Graham BS, Chiu YL et al. Breakthrough infections during Phase 1 and 2 prime-boost HIV-1 vaccine trials with canarypox vectors (ALVAC) and booster dose of recombinant gp120 or gp160. J. Infect. Dis. 190(5), 903-907 (2004).
130. Pitisuttithum P, Nitayaphan S, Thongcharoen P et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodefciency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J. Infect. Dis. 188(2), 219-227 (2003).
131. VanCott TC, Mascola JR, Kaminski RW et al. Antibodies with specifcity to native gp120 and neutralization activity against primary human immunodefciency virus type 1 isolates elicited by immunization with oligomeric gp160. J. Virol. 71(6), 4319-4330 (1997).
132. Fouts TR, Binley JM, Trkola A, Robinson JE, Moore JP. Neutralization of the human immunodefciency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 71(4), 2779-2785 (1997).
133. Nitayaphan S, Pitisuttithum P, Karnasuta C et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J. Infect. Dis. 190(4), 702-706 (2004).
134. ® B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23(19), 2522-2529 (2005).
135. Michael NL. Primary and sub-group analyses of the Thai Phase III HIV vaccine trial. Presented at: AIDS Vaccine 2009. Paris, France, 19-22 October 2009.
136. Patterson LJ, Robert-Guroff M. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert. Opin. Biol. Ther. 8(9), 1347-1363 (2008).
137. Rosario M, Hopkins R, Fulkerson J et al. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modifed vaccinia virus ankara vaccines combine to induce robust human immunodefciency virus-specifc CD4 and CD8 T-cell responses in rhesus macaques. J. Virol. 84(12), 5898-5908 (2010).
138. Barnett SW, Srivastava IK, Kan E et al. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope. AIDS 22(3), 339-348 (2008).
139. Bennett MS, Ng HL, Ali A, Yang OO. Cross-clade detection of HIV-1-specifc cytotoxic T lymphocytes does not refect cross-clade antiviral activity. J. Infect. Dis. 197(3), 390-397 (2008).
140. + T-cell recognition of simian immunodefciency virus-infected cells expressing the same variant sequences. J. Virol. 82(1), 575-581 (2008).
141. Spentzou A, Bergin P, Gill D et al. Viral inhibition assay: a CD8 T cell neutralization assay for use in clinical trials of HIV-1 vaccine candidates. J. Infect. Dis. 201(5), 720-729 (2010).
142. Bull M, Lee D, Stucky J et al. Defning blood processing parameters for optimal detection of cryopreserved antigen-specifc responses for HIV vaccine trials. J. Immunol. Methods 322(1-2), 57-69 (2007).
143. Kierstead LS, Dubey S, Meyer B et al. Enhanced rates and magnitude of immune responses detected against an HIV vaccine: effect of using an optimized process for isolating PBMC. AIDS Res. Hum. Retroviruses 23(1), 86-92 (2007).
144. Sun Y, Iglesias E, Samri A et al. A systematic comparison of methods to measure HIV-1 specifc CD8 T cells. J. Immunol. Methods 272(1-2), 23-34 (2003).
145. D'Souza MP, Altfeld M. Measuring HIV-1-specifc T cell immunity: how valid are current assays? J. Infect. Dis. 197(3), 337-339 (2008).
146. Horton H, Thomas EP, Stucky JA et al. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specifc T cells induced by vaccination. J. Immunol. Methods 323(1), 39-54 (2007).
147. Mascola JR, D'Souza P, Gilbert P et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodefciency virus type 1 vaccines. J. Virol. 79(16), 10103-10107 (2005).
148. + T cell responses with distinct clonotype and epitope specifcity. J. Immunol. 183(4), 2425-2434 (2009).
149. Kaslow RA, Rivers C, Tang J et al. Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodefciency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. J. Virol. 75(18), 8681-8689 (2001).
150. Paris R, Bejrachandra S, Karnasuta C et al. HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodefciency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. Tissue Antigens 64(3), 251-256 (2004).
151. Trotter CL, Ramsay ME, Slack MP. Rising incidence of Haemophilus infuenzae type b disease in England and Wales indicates a need for a second catch-up vaccination campaign. Commun. Dis. Public Health 6(1), 55-58 (2003).
152. Trotter CL, McVernon J, Andrews NJ, Burrage M, Ramsay ME. Antibody to Haemophilus infuenzae type b after routine and catch-up vaccination. Lancet 361(9368), 1523-1524 (2003).
153. Tacket CO, Sack DA. Cholera vaccines. In: Vaccines 5th edition. Plotkin S, Orenstein W, Offt P (Eds). WB Saunders Company, PA, USA, 127-138 (2008).
154. Simek MD, Rida W, Priddy FH et al. HIV-1 elite neutralizers: individuals with broad and potent neutralizing activity identifed using a high throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83(14), 7337-7348 (2009).
155. Walker LM, Phogat SK, Chan-Hui PY et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285-289 (2009).
156. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat. Rev. Immunol. 10(1), 11-23 (2010).
157. + cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. 180(2), 290-298 (1999).
158. Cleghorn F, Pape JW, Schechter M et al. Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J. Acquir. Immune Defc. Syndr. 46(2), 222-230 (2007).